| SC 13D/A | 2024-04-01 | TCG Crossover GP I, LLC | KalVista Pharmaceuticals, Inc. | 1,345,826 | 3.2% | EDGAR |
| SC 13G | 2024-02-26 | ADAGE CAPITAL PARTNERS GP, L.L.C. | KalVista Pharmaceuticals, Inc. | 2,845,000 | 6.9% | EDGAR |
| SC 13D/A | 2024-02-22 | Frazier Life Sciences Public Fund, L.P. | KalVista Pharmaceuticals, Inc. | 1,504,956 | 3.6% | EDGAR |
| SC 13D/A | 2024-02-20 | TCG Crossover GP I, LLC | KalVista Pharmaceuticals, Inc. | 2,700,840 | 6.5% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners III, L.P. | KalVista Pharmaceuticals, Inc. | 4,824,731 | 14.0% | EDGAR |
| SC 13G/A | 2024-02-14 | TANG CAPITAL PARTNERS LP | KalVista Pharmaceuticals, Inc. | 3,440,345 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | KalVista Pharmaceuticals, Inc. | 2,684,005 | 7.8% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | KalVista Pharmaceuticals, Inc. | 1,781,419 | 5.2% | EDGAR |
| SC 13G | 2024-02-12 | Saturn V Capital Management LP | KalVista Pharmaceuticals, Inc. | 1,431,259 | 4.1% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | KalVista Pharmaceuticals, Inc. | 50,970 | 0.1% | EDGAR |
| SC 13G | 2024-01-29 | BlackRock Inc. | KalVista Pharmaceuticals, Inc. | 2,242,025 | 6.5% | EDGAR |
| SC 13G/A | 2023-12-28 | Venrock Healthcare Capital Partners III, L.P. | KalVista Pharmaceuticals, Inc. | 3,573,714 | 10.3% | EDGAR |
| SC 13D/A | 2023-12-14 | Frazier Life Sciences Public Fund, L.P. | KalVista Pharmaceuticals, Inc. | 1,455,861 | 4.2% | EDGAR |
| SC 13G | 2023-03-10 | SUVRETTA CAPITAL MANAGEMENT, LLC | KalVista Pharmaceuticals, Inc. | 1,796,379 | 5.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | KalVista Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | GREAT POINT PARTNERS LLC | KalVista Pharmaceuticals, Inc. | 1,055,801 | 3.1% | EDGAR |
| SC 13G/A | 2023-02-14 | Vivo Capital IX, LLC | KalVista Pharmaceuticals, Inc. | 83 | 0.2% | EDGAR |
| SC 13G/A | 2023-02-14 | TANG CAPITAL PARTNERS LP | KalVista Pharmaceuticals, Inc. | 3,196,446 | 9.4% | EDGAR |
| SC 13G/A | 2023-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | KalVista Pharmaceuticals, Inc. | 1,072,302 | 3.1% | EDGAR |
| SC 13G | 2023-02-09 | FMR LLC | KalVista Pharmaceuticals, Inc. | 1,311,002 | 5.3% | EDGAR |